Abstract：
OBJECTIVE: The prevalence of benzodiazepines and related drugs (BZRDs) use during pregnancy increased sharply in recent years. Thus, there are concerns regarding the pregnancy outcomes following exposure to BZRDs.
METHODS: Two electronic databases were thoroughly searched to identify related clinical studies published from inception until June 2023. English-language cohort studies with high-quality comparing antenatal BZRDs exposure to an unexposed group on any delivery outcome were included.
RESULTS: Ten cohort studies that estimated adverse neonatal outcomes associated with exposure to BZRDs during pregnancy were included. Exposure to BZRDs during pregnancy was associated with an increased risk of congenital malformation [odds ratio (OR) 1.09, 95% confidence interval (CI) 1.05-1.13, p < 0.001], heart malformation (OR 1.13, 95% CI 1.04-1.22, p = 0.003), preterm birth (OR 1.45, 95% CI 1.23-1.7, p < 0.001), SGA (OR 1.18, 95% CI 1.08-1.29, P < 0.001), LBW (OR 1.42, 95% CI 1.25-1.6, p = 0.001) or low Apgar score (OR 1.42, 95% CI 1.08-1.87, p = 0.011),compared with no exposure. Further analyses limited to the first trimester exposure yielded consistent results.
CONCLUSIONS: Exposure to BZRDs during pregnancy may be associated with several adverse neonatal outcomes. However, we could not rule out the potential indication confounding factor, further studies with high-quality that control for important confounders are still needed to verify our findings.
METHODS: Two electronic databases were thoroughly searched to identify related clinical studies published from inception until June 2023. English-language cohort studies with high-quality comparing antenatal BZRDs exposure to an unexposed group on any delivery outcome were included.
RESULTS: Ten cohort studies that estimated adverse neonatal outcomes associated with exposure to BZRDs during pregnancy were included. Exposure to BZRDs during pregnancy was associated with an increased risk of congenital malformation [odds ratio (OR) 1.09, 95% confidence interval (CI) 1.05-1.13, p < 0.001], heart malformation (OR 1.13, 95% CI 1.04-1.22, p = 0.003), preterm birth (OR 1.45, 95% CI 1.23-1.7, p < 0.001), SGA (OR 1.18, 95% CI 1.08-1.29, P < 0.001), LBW (OR 1.42, 95% CI 1.25-1.6, p = 0.001) or low Apgar score (OR 1.42, 95% CI 1.08-1.87, p = 0.011),compared with no exposure. Further analyses limited to the first trimester exposure yielded consistent results.
CONCLUSIONS: Exposure to BZRDs during pregnancy may be associated with several adverse neonatal outcomes. However, we could not rule out the potential indication confounding factor, further studies with high-quality that control for important confounders are still needed to verify our findings.
摘要：
目的：近年来妊娠期使用苯二氮卓类药物及相关药物（BZRD）的患病率急剧上升。因此，对于暴露于BZRD后的妊娠结局存在担忧.
方法：彻底搜索了两个电子数据库，以确定从开始到2023年6月发表的相关临床研究。包括高质量的英语队列研究，比较产前BZRD暴露于未暴露组的任何分娩结果。
结果：纳入了10项估计与孕期暴露于BZRD相关的不良新生儿结局的队列研究。怀孕期间暴露于BZRD与先天性畸形的风险增加相关[优势比（OR）1.09，95％置信区间（CI）1.05-1.13，p<0.001]，心脏畸形（OR1.13，95%CI1.04-1.22，p=0.003），早产（OR1.45，95%CI1.23-1.7，p<0.001），SGA（OR1.18，95%CI1.08-1.29，P<0.001），LBW（OR1.42，95％CI1.25-1.6，p=0.001）或低Apgar评分（OR1.42，95％CI1.08-1.87，p=0.011），与没有暴露相比。仅限于妊娠早期暴露的进一步分析产生了一致的结果。
结论：孕期暴露于BZRD可能与几种不良新生儿结局有关。然而,我们不能排除潜在的指征混杂因素，仍需要对重要混杂因素进行高质量控制的进一步研究来验证我们的发现.
方法：彻底搜索了两个电子数据库，以确定从开始到2023年6月发表的相关临床研究。包括高质量的英语队列研究，比较产前BZRD暴露于未暴露组的任何分娩结果。
结果：纳入了10项估计与孕期暴露于BZRD相关的不良新生儿结局的队列研究。怀孕期间暴露于BZRD与先天性畸形的风险增加相关[优势比（OR）1.09，95％置信区间（CI）1.05-1.13，p<0.001]，心脏畸形（OR1.13，95%CI1.04-1.22，p=0.003），早产（OR1.45，95%CI1.23-1.7，p<0.001），SGA（OR1.18，95%CI1.08-1.29，P<0.001），LBW（OR1.42，95％CI1.25-1.6，p=0.001）或低Apgar评分（OR1.42，95％CI1.08-1.87，p=0.011），与没有暴露相比。仅限于妊娠早期暴露的进一步分析产生了一致的结果。
结论：孕期暴露于BZRD可能与几种不良新生儿结局有关。然而,我们不能排除潜在的指征混杂因素，仍需要对重要混杂因素进行高质量控制的进一步研究来验证我们的发现.
